Diffuse large B-cell lymphoma stage III

2 trials MedDRA PT
2 Registered trials
0 Recruiting
2 Unique sponsors
9 Unique IMPs
1 Commercial trials
Drug classes (ATC)
— ATC code not specified 1
H Endocrinology (ATC H) 1
L Oncology (ATC L) 1
Mechanism of action (INN-stem analysis)
CAR-T cell therapy 1 substance
Unknown / small molecule 1 substance
Platinum compound 1 substance
Antimetabolite 1 substance
Corticosteroid 1 substance
IMiD 1 substance
Antibody-drug conjugate (ADC) 1 substance
Monoclonal antibody (chimeric) 1 substance
Monoclonal antibody (rat) 1 substance
Phase II: 1 Phase I (Other): 1

Filter these 2 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 2 trials

Phase II

1 trial
  • Instytut Hematologii I Transfuzjologii Academic
    AXICABTAGENE CILOLEUCEL; BENDAMUSTINE HYDROCHLORIDE; CISPLATIN; CYTARABINE; DEXAMETHASONE; LENALIDOMIDE; POLATUZUMAB VEDOTIN; RITUXIMAB; TAFASITAMAB
    2024-518275-64-00 1 country n=340 Orphan
    Pending

Phase I (Other)

1 trial
  • Pfizer Inc. Commercial
    IMP not specified
    2024-517756-35-00 1 country 2025 n=33
    Ended
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Pfizer Inc. Commercial 1 Phase I (Other) 0
Instytut Hematologii I Transfuzjologii Academic 1 Phase II 0
New trials by year
2025
1
← All indication landscapes